DNMT3A

Biomarkers /

Back to Biomarkers List

Associated Genetic Biomarkers

DNMT3A Amplification
DNMT3A Frameshift
DNMT3A Loss
DNMT3A Nonsense
DNMT3A R882C
DNMT3A R882G
DNMT3A R882H
DNMT3A R882L
DNMT3A R882P
DNMT3A R882S
DNMT3A Mutation

Associated Diseases

Ovarian Carcinoma
Melanoma
Pancreatic Carcinoma
Myelodysplastic Syndromes
Sarcoma
Refractory Cytopenia with Multilineage Dysplasia
Non-Small Cell Lung Carcinoma
Bladder Carcinoma
Breast Carcinoma
Refractory Anemia with Excess Blasts
Refractory anemia with ring sideroblasts
Colorectal Carcinoma
Chronic Myelomonocytic Leukemia
Lymphoma
Acute Myeloid Leukemia
Head and Neck Carcinoma

Associated Pathways

Chromatin remodeling/DNA methylation

Overview

Location [1]

2p23.3

Pathway

Chromatin remodeling/DNA methylation

Synonyms [1]

HESJAS, DNMT3A2, TBRS, M.HsaIIIA

DNMT3A (DNA (cytosine-5-)-methyltransferase 3 alpha) gene encodes the DNA (cytosine-5)-methyltransferase 3A protein, which is involved in epigenetic gene regulation (Gene 2013; PMID: 17938196). DNMT3A is most frequently mutated in hematologic malignancies, but it has also been observed in other cancers, including lung cancer (PMID: 23031157).

Clinical Trials

View Clinical Trials for DNMT3A

DNMT3A status serves as an inclusion eligibility criteria in 5 clinical trials, of which 3 are open and 2 are closed. Of the trials that contain DNMT3A status as an inclusion criterion, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (1 open).

Trials with DNMT3A status in the inclusion eligibility criteria most commonly target acute myeloid leukemia, bladder carcinoma, breast carcinoma, chronic myelomonocytic leukemia, and colorectal carcinoma [4].

Trials Investigating DNMT3A by Disease and Recruiting Status

The most frequent alterations to serve as inclusion eligibility criteria are DNMT3A Loss and DNMT3A Mutation [4].

Trials Investigating DNMT3A by Alteration and Recruiting Status

Fludarabine, busulfan, granulocyte colony-stimulating factor, tacrolimus, and allogeneic cd56-positive cd3-negative natural killer cells are the most frequent therapies in trials with DNMT3A as an inclusion criteria [4].

Drugs Being Investigated in DNMT3A Trials by Recruiting Status

Significance of DNMT3A in Diseases

Acute Myeloid Leukemia +

DNMT3A is an inclusion criterion in 4 clinical trials for acute myeloid leukemia, of which 3 are open and 1 is closed. Of the trials that contain DNMT3A status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (1 open) [4].

Myelodysplastic Syndromes +

DNMT3A is an inclusion criterion in 4 clinical trials for myelodysplastic syndromes, of which 3 are open and 1 is closed. Of the trials that contain DNMT3A status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (1 open) [4].

Chronic Myelomonocytic Leukemia +

DNMT3A is an inclusion criterion in 3 clinical trials for chronic myelomonocytic leukemia, of which 3 are open and 0 are closed. Of the trials that contain DNMT3A status and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

Chronic Myeloid Leukemia +

DNMT3A is an inclusion criterion in 2 clinical trials for chronic myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain DNMT3A status and chronic myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

Acute Lymphoblastic Leukemia +

DNMT3A is an inclusion criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains DNMT3A status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

Anaplastic Astrocytoma +

DNMT3A is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains DNMT3A status and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [4].

Aplastic Anemia +

DNMT3A is an inclusion criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains DNMT3A status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [4].

Bladder Carcinoma +

DNMT3A is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains DNMT3A status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

Breast Carcinoma +

DNMT3A is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains DNMT3A status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma +

DNMT3A is an inclusion criterion in 1 clinical trial for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains DNMT3A status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

Colorectal Carcinoma +

DNMT3A is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains DNMT3A status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

Glioblastoma +

DNMT3A is an inclusion criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains DNMT3A status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [4].

Head And Neck Carcinoma +

DNMT3A is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains DNMT3A status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

Hodgkin Lymphoma +

DNMT3A is an inclusion criterion in 1 clinical trial for hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains DNMT3A status and hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

Lymphoblastic Lymphoma +

DNMT3A is an inclusion criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains DNMT3A status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

Lymphoma +

DNMT3A is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains DNMT3A status and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

Malignant Solid Tumor +

DNMT3A is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains DNMT3A status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [4].

Melanoma +

DNMT3A is an inclusion criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains DNMT3A status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [4].

Multiple Myeloma +

DNMT3A is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains DNMT3A status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) [4].

Non-Hodgkin Lymphoma +

DNMT3A is an inclusion criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains DNMT3A status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

Non-Small Cell Lung Carcinoma +

DNMT3A is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains DNMT3A status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

Ovarian Carcinoma +

DNMT3A is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains DNMT3A status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

Pancreatic Carcinoma +

DNMT3A is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains DNMT3A status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

Sarcoma +

DNMT3A is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains DNMT3A status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

Therapy-Related Chronic Myelomonocytic Leukemia +

DNMT3A is an inclusion criterion in 1 clinical trial for therapy-related chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains DNMT3A status and therapy-related chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

Therapy-Related Myelodysplastic Syndrome +

DNMT3A is an inclusion criterion in 1 clinical trial for therapy-related myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains DNMT3A status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [4].

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.